España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Harbor ETF Trust Harbor Multi-Asset Explorer ETF
MAPP
ARCA
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
Get Report
Comment
Overview
News
Holdings
Dividends
Short Interest
Latest news for Harbor ETF Trust Harbor Multi-Asset Explorer ETF (ARCA:MAPP)
Harbor ETF Trust Harbor Multi-Asset Explorer ETF (ARCA: MAPP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 01, 2013
UPDATE: Wedbush Downgrades MAP Pharmaceuticals to Neutral, Reiterates $25 PT on Likely Acquisition
Benzinga
Wedbush Downgrades MAP Pharmaceuticals, Inc. to Neutral, Maintains $25.00 PT
Benzinga
Allergan Announces Intent to Exercise Top-Up ...
Benzinga
Friday, February 15, 2013
2013: Year of the Mega Deal
Benzinga
Thursday, February 07, 2013
Allergan, Map Pharma Announce FTC Grants Earl...
Benzinga
Friday, February 01, 2013
Ladenburg Thalmann Downgrades MAP Pharmaceuticals, Inc. to Neutral
Benzinga
Wednesday, January 30, 2013
Map Pharmaceuticals Spikes Higher
Benzinga
Monday, January 28, 2013
UPDATE: Deutsche Bank Downgrades MAP Pharmaceuticals to Hold Following Acquisition Bid
Benzinga
Deutsche Bank Downgrades MAP Pharmaceuticals, Inc. to Hold, Raises PT to $25.00
Benzinga
Thursday, January 24, 2013
UPDATE: Canaccord Genuity Downgrades MAP Pharmaceuticals to Hold Following Takeover
Benzinga
Canaccord Genuity Downgrades MAP Pharmaceuticals, Inc. to Hold, Raises PT to $25.00
Benzinga
Wednesday, January 23, 2013
Benzinga's M&A Chatter for Wednesday January 23, 2013
Benzinga
Leerink Swann Downgrades MAP Pharmaceuticals, Inc. to Market Perform
Benzinga
Mid-Day Market Update: AMD Remains Up, Cyberonics Takes a Beating
Benzinga
MAP Skyrockets Off the Map on Allergan Acquisition
Benzinga
Mid-Morning Market Update: Cree Continues Earnings Fueled Rally, General Dynamics Feels Defense Spending Slowdown
Benzinga
Allergan to Acquire MAP Pharmaceuticals for $25.00/Share
Benzinga
Friday, November 23, 2012
Morning Market Movers
Benzinga
Wedbush Securities Reiterates Outperform Rating on MAP Pharmaceuticals
Benzinga
MAP Pharma Shares Up 14% as FDA Accepts NDA R...
Benzinga
Wednesday, August 01, 2012
MAP Pharmaceuticals, Inc. Prices 3.88M Common Share Public Offering at $13.40 Per Share
Benzinga
Tuesday, July 31, 2012
MAP Pharmaceuticals Announces Proposed Public Offering of Common Stock
Benzinga
Friday, July 13, 2012
Social Media Outlook, Friday July 13
Benzinga
Thursday, July 12, 2012
Map Pharmaceuticals Spikes Lower on FDA Posting
Benzinga
Monday, June 25, 2012
MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX NDA; Company plans to resubmit in late Q3/early Q4 2012
Benzinga
Monday, May 07, 2012
Ladenburg Thalmann Reiterates Buy Rating, $24 PT for MAP Pharmaceuticals
Benzinga
UPDATE: J.P. Morgan Decreases PT on MAP Pharmaceuticals
Benzinga
JP Morgan Maintains MAP Pharmaceuticals at Ov...
Benzinga
Friday, May 04, 2012
MAP Pharmaceuticals Reports Q1 EPS $-0.58 vs $-0.39 Est; Revenues $1.0M vs $1.10M Est
Benzinga
Thursday, April 12, 2012
MAP Pharmaceuticals Provides Update on LEVADEX Program
Benzinga
Friday, March 30, 2012
MAP Pharmaceuticals Releases 10Q
Benzinga
Thursday, March 29, 2012
MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results
Benzinga
MAP To Correct Accounting For $60M Upfront Pa...
Benzinga
Wednesday, March 28, 2012
Morning Social Media Outlook for Wednesday March 28 (PNR, FDO, SNX, MMR)
Benzinga
UPDATE: Ladenburg Thalmann Reiterates Buy for Map Pharmaceuticals and $24 PT
Benzinga
Tuesday, March 27, 2012
Wedbush Securities Maintains MAP Pharmaceutic...
Benzinga
MAP Pharmaceuticals Trading 0.8% Lower on Hea...
Benzinga
Morning Social Media Outlook for Tuesday March 27 (ISTA, LNDC, CALM, MAPP)
Benzinga
MAP Pharmaceuticals Trading 10.7% Lower on He...
Benzinga
UPDATE: Map Says It Will Provide Updates on F...
Benzinga
UPDATE: MAP Says FDA Didn't Mention Concerns ...
Benzinga
UPDATE: MAP Pharma Will Request FDA Meeting T...
Benzinga
MAP CEO Says Approval Milestone with Allergan...
Benzinga
MAP Pharma Falls as Much as 35% on CRL
Benzinga
UPDATE: MAP CEO Says FDA Wanted More Time to ...
Benzinga
UPDATE: MAP CEO Says FDA Had Questions on Inh...
Benzinga
MAP CEO Says Third-Party Manufacturer was FDA...
Benzinga
Benzinga's Top Pre-Market Losers
Benzinga
MAP Pharma Says FDA Didn't Require More Clini...
Benzinga
JP Morgan on MAP Pharmaceuticals Delayed Approval of Levadex
Benzinga
Show More